A Two-part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Oral Doses of Pazopanib in Healthy Adult Subjects

Trial Profile

A Two-part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Oral Doses of Pazopanib in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2015

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Acute myeloid leukaemia; Age-related macular degeneration; Bladder cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Fallopian tube cancer; Gallbladder cancer; Glioma; Hereditary haemorrhagic telangiectasia; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cancer; Sarcoma; Solid tumours; Thyroid cancer
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 16 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top